Human Pilot Study for the Investigation of the Role of Bilberry and Olive Bioactives on Oxidative Stress Parameters and Inflammatory Markers. (BIOTRANSFORM)
A Blinded Placebo-controlled Human Pilot Study for the Investigation of the Role of Bilberry and Olive Bioactives on Oxidative Stress Parameters and Inflammatory Markers. Relevance in European Population
Numerous plant-based foods contain bioactive compounds, in particular polyphenols, which have antioxidant, anti-inflammatory, and metabolic regulatory effects. These so-called food bioactives (FB) are converted in the human organism, in particular by the gut microbiota and microsomal (liver/intestinal) metabolism, into numerous metabolites, which often represent the actual biologically active molecules. As part of the European HORIZON-MSCA Doctoral Network "BioTransform," two such food models are being studied as examples: 1. Olive products (Olea europaea L.) - representative of the Mediterranean diet, rich in secoiridoids and phenylethanols (especially hydroxytyrosol and tyrosol). 2.
Bilberry /blueberry (Vaccinium myrtillus L.) - representative of the Central European diet, rich in anthocyanosides. Two parallel human intervention studies will be conducted, one in Graz (WP1, DC5) and one in Athens (WP1, DC3). These pilot studies will generate biological samples (blood, urine, stool) and investigate the extent to which taking these standardized dietary supplements influences glucose metabolism and markers of oxidative stress and low-grade inflammation.
研究概览
地位
地位
条件
条件
干预/治疗
干预/治疗
研究类型
研究类型
注册 (估计的)
注册
阶段
阶段
- 不适用
联系人和位置
学习地点
-
-
-
Athens、希腊、11527
- Laiko Hospital
-
接触:
- NIKOLAOS TENTOLOURIS, PROFESSOR MD, PHD
- 电话号码:+30 2132061061
- 邮箱:ntentol@meduoa.gr
-
-
参与标准
资格标准
资格标准
适合学习的年龄
- 成人
接受健康志愿者
描述
Inclusion Criteria:
- 30-50 years old,
- BMI> 25 kg/m2
- prediabetic stage
- hsCRP> 2mg/ L
- HbA1c 5,7-6,4%
- Impaired fasting glucose (IFG)
- Caucasian
Exclusion Criteria:
- No signed informed consent
- Supplementation or probiotic usage in the past 8 weeks
- Chronic gastrointestinal, inflammatory or metabolic diseases
- Alcohol misuse
- Pregnancy or breastfeeding
- Acute infection during the past month
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:随机化
- 介入模型:交叉作业
- 屏蔽:单身的
手臂数量
武器和干预
参与者组/臂参与者组/臂 |
干预/治疗干预/治疗 |
|---|---|
|
实验性的:INTERVENTION WITH OLIVE OIL EXTRACTS
Group of 20 people will receive olive oil extract supplements and after the washout period will receive placebo.
|
Through this pilot clinical study, the possible change of inflammatory and oxidative stress biomarkers in prediabetic, overweigh/ obese people will be observed.
Blood, urine and stool samples will be collected, while weight mangment will also be controlled.
其他名称:
|
|
实验性的:INTERVENTION WITH BILBERRY
Group of 20 participants will receive bilberry extract supplements and after the washout period a placebo phase.
|
Through this pilot clinical study, the possible change of inflammatory and oxidative stress biomarkers in prediabetic, overweigh/ obese people will be observed.
Blood, urine and stool samples will be collected, while weight mangment will also be controlled.
其他名称:
|
研究衡量的是什么?
主要结果指标
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Changes in inflammatory and oxidative stress markers
大体时间:14 weeks
|
The changes in the inflammatory and oxidative stress markers will be assessed through blood samples and the biomarkers: hsCRP, IL-6, TNF-a, total antioxidant capacity, ratio glutathione/ oxidiced glutathion
|
14 weeks
|
次要结果测量
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Lipid profile
大体时间:14 weeks
|
Blood samples: TCHOL, HDL, LDL, TG
|
14 weeks
|
|
Inflammatory profile
大体时间:14 weeks
|
Blood samples: ICAM-1, VCAM-1, CRP-C
|
14 weeks
|
|
Anthropometric profile
大体时间:14 weeks
|
Body measurements: BMI and body weight changes
|
14 weeks
|
|
Metabolic profile
大体时间:14 weeks
|
Urine and plasma samples: metabolite profile in urine and plasma
|
14 weeks
|
|
Microbiome profile
大体时间:14 weeks
|
Stool samples: microbiome diversity, microbiome composition changes, and microbiome functionality
|
14 weeks
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
学习开始
初级完成 (估计的)
初级完成
研究完成 (估计的)
研究完成
研究注册日期
首次提交
首次提交
首先提交符合 QC 标准的
首先提交符合 QC 标准的
首次发布 (实际的)
首次发布
研究记录更新
最后更新发布 (实际的)
最后更新发布
上次提交的符合 QC 标准的更新
上次提交的符合 QC 标准的更新
最后验证
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
其他研究编号
- 999643007
- 101225248 (其他赠款/资助编号:Marie Skłodowska-Curie Actions)
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.